Gilead Sciences Acquires CymaBay Therapeutics for $4.3 Billion

Gilead Sciences Acquires XinThera

May 9, 2023

Biotechnology

Gilead Sciences has acquired all outstanding shares of XinThera, a San Diego–based private biotechnology company, adding small-molecule oncology and inflammation programs (including PARP1-selective and MK2-targeting assets) to its early pipeline. Financial terms were not disclosed; XinThera was backed by investors including Foresite Capital, OrbiMed and TTM Capital.

Ipsen Acquires Albireo Pharma

January 9, 2023

Biotechnology

Ipsen has agreed to acquire Albireo Pharma in a cash tender offer of $42.00 per share plus a contingent value right (CVR) tied to FDA approval in biliary atresia, in a transaction intended to expand Ipsen's Rare Disease portfolio. The acquisition brings Albireo's approved pediatric liver drug Bylvay (odevixibat) and a pipeline of bile-acid modulators into Ipsen's global R&D and commercial capabilities.

Gilead Sciences Acquires MiroBio

September 20, 2022

Biotechnology

Gilead Sciences completed the acquisition of U.K.-based biotechnology company MiroBio for approximately $405 million in cash. The deal gives Gilead MiroBio's discovery platform and portfolio of immune inhibitory receptor agonists, including lead investigational antibody MB272, which is in Phase 1 clinical trials.

Bayer AG Acquires Asklepios BioPharmaceutical (AskBio)

October 26, 2020

Biotechnology

Bayer AG agreed to acquire U.S.-headquartered Asklepios BioPharmaceutical (AskBio), adding AskBio's AAV-based gene therapy platform, IP and CDMO manufacturing capabilities to Bayer’s emerging cell and gene therapy unit. Bayer will pay $2.0 billion upfront plus up to $2.0 billion in potential milestone payments; existing minority shareholders TPG Capital and Vida Ventures supported the transaction.

Gilead Sciences Acquires Immunomedics

September 13, 2020

Biotechnology

Gilead Sciences agreed to acquire Immunomedics for $88.00 per share in an all-cash transaction valuing Immunomedics at approximately $21 billion. The acquisition gives Gilead global rights (outside certain Asian territories) to Trodelvy, an FDA‑approved antibody‑drug conjugate for metastatic triple‑negative breast cancer, and accelerates Gilead’s expansion into oncology.

Gilead Sciences Acquires Forty Seven for $4.9 Billion

March 2, 2020

Biotechnology

Gilead Sciences agreed to acquire clinical-stage immuno-oncology company Forty Seven for $95.50 per share in cash, valuing the deal at approximately $4.9 billion. The acquisition adds Forty Seven's lead investigational antibody magrolimab to Gilead's oncology pipeline and is expected to close in Q2 2020 subject to customary approvals.